CAPRICOR THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
CAPRICOR THERAPEUTICS, INC. (CAPR) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 123.00% for the 3-month period ending 2022-03-31, per its 10-Q filed 2023-05-12.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2023-05-12
- CAPRICOR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2022-03-31 was 123.00%, a 0.81% decline year-over-year.
- CAPRICOR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2021-03-31 was 124.00%.
- CAPRICOR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2016-03-31 was 79.00%, a 3.66% decline year-over-year.
- CAPRICOR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2015-03-31 was 82.00%, a 29.91% decline year-over-year.
- CAPRICOR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2013 was 118.00%, a 18.00% increase from fiscal 2012.
- CAPRICOR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2012 was 100.00%, a 3.09% increase from fiscal 2011.
- CAPRICOR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2011 was 97.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month |
|---|---|---|---|---|
| 2022-03-31 | 123.00% 10-Q · filed 2023-05-12 | |||
| 2021-03-31 | 124.00% 10-Q · filed 2022-05-11 | |||
| 2016-03-31 | 79.00% 10-Q · filed 2017-05-15 | |||
| 2015-03-31 | 82.00% 10-Q · filed 2016-05-13 | |||
| 2014-09-30 | 112.00% 10-Q · filed 2014-11-14 | |||
| 2014-06-30 | 115.00% 10-Q · filed 2014-08-14 | |||
| 2014-03-31 | 117.00% 10-Q · filed 2015-05-13 | |||
| 2013-12-31 | 118.00% 10-K · filed 2015-03-16 | |||
| 2013-09-30 | 100.00% 10-Q · filed 2014-11-14 | |||
| 2013-06-30 | 100.00% 10-Q · filed 2014-08-14 | |||
| 2013-03-31 | 100.00% 10-Q · filed 2014-05-15 | |||
| 2012-12-31 | 100.00% 10-K · filed 2014-03-31 | |||
| 2011-12-31 | 97.00% 10-K · filed 2013-06-21 | |||
| 2011-09-30 | 97.00% 10-Q · filed 2013-06-21 | |||
| 2011-06-30 | 97.00% 10-Q/A · filed 2012-09-10 | 97.00% 10-Q/A · filed 2012-09-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |